Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
28 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 – – Prospective data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH 2018 – ...
Kura Oncology to Report Third Quarter 2018 Financial Results
29 oct. 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
22 oct. 2018 08h45 HE
|
Kura Oncology, Inc.
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
26 sept. 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Second Quarter 2018 Financial Results
30 juil. 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at JMP Securities Life Sciences Conference
14 juin 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
12 mars 2018 16h05 HE
|
Kura Oncology, Inc.
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59...
Kura Oncology Announces Pricing of Public Offering of Common Stock
10 août 2017 22h11 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Second Quarter 2017 Financial Results
31 juil. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
18 juil. 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...